Crossmark

Publisher Correction: Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study

Crossref DOI link: https://doi.org/10.1038/s42255-022-00635-4

Published Online: 2022-08-16

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Puurunen, Marja K. https://orcid.org/0000-0003-3810-5687
Vockley, Jerry

Searle, Shawn L.

Sacharow, Stephanie J.

Phillips, John A. III

Denney, William S. https://orcid.org/0000-0002-5759-428X
Goodlett, Benjamin D.

Wagner, David A.

Blankstein, Larry

Castillo, Mary J.

Charbonneau, Mark R. https://orcid.org/0000-0003-4893-8244
Isabella, Vincent M.

Sethuraman, Vasu V.

Riese, Richard J.

Kurtz, Caroline B. https://orcid.org/0000-0001-7192-6116
Brennan, Aoife M.
License Information

Text and Data Mining valid from 2022-08-16

Version of Record valid from 2022-08-16
More Information

Article History

First Online: 16 August 2022

Free to read: This content has been made available to all.

Document is current

Any future updates will be listed below